T1	PROC 46 72	Ensayo Clínico de fase III
#1	AnnotatorNotes T1	C0282461; Phase 3 Clinical Trials; Research Activity
T2	CHEM 77 89	caplacizumab
#2	AnnotatorNotes T2	C3713057; caplacizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	DISO 107 152	púrpura trombocitopénica trombótica adquirida
#3	AnnotatorNotes T3	C2584778; Thrombotic thrombocytopenic purpura, acquired; Disease or Syndrome
T4	PROC 175 287	Ensayo clínico de fase III, doble ciego, aleatorizado de grupos paralelos, multicéntrico, controlado con placebo
T5	PROC 294 329	estudiar la eficacia y la seguridad
T6	CHEM 333 345	caplacizumab
#4	AnnotatorNotes T6	C3713057; caplacizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T7	DISO 363 408	púrpura trombocitopénica trombótica adquirida
#5	AnnotatorNotes T7	C2584778; Thrombotic thrombocytopenic purpura, acquired; Disease or Syndrome
T8	DISO 435 438	PTT
#6	AnnotatorNotes T8	C0034155; Purpura, Thrombotic Thrombocytopenic; Disease or Syndrome
T9	DISO 446 461	enfermedad rara
#7	AnnotatorNotes T9	C0678236; Rare Diseases; Disease or Syndrome
T10	ANAT 514 520	sangre
#8	AnnotatorNotes T10	C0005767; Blood; Body Substance
T11	DISO 543 551	coágulos
#9	AnnotatorNotes T11	C0302148; Blood Clot; Pathologic Function
T12	ANAT 559 575	vasos sanguíneos
#10	AnnotatorNotes T12	C0005847; Blood Vessel; Body Part, Organ, or Organ Component | C1283786; Entire blood vessel; Body Part, Organ, or Organ Component
T13	ANAT 600 606	cuerpo
#11	AnnotatorNotes T13	C0460148; Human body structure; Anatomical Structure | C1318419; Entire human body; Anatomical Structure
T14	DISO 634 679	Púrpura trombocitopénica trombótica adquirida
#12	AnnotatorNotes T14	C2584778; Thrombotic thrombocytopenic purpura, acquired; Disease or Syndrome
T15	PROC 796 820	consentimiento informado
#13	AnnotatorNotes T15	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T16	PROC 830 849	Diagnóstico clínico
#14	AnnotatorNotes T16	C0332140; Diagnosis, clinical; Diagnostic Procedure
T17	DISO 853 866	PTT adquirida
#15	AnnotatorNotes T17	C2584778; Thrombotic thrombocytopenic purpura, acquired; Disease or Syndrome
T18	PROC 1239 1258	número de plaquetas
T19	DISO 903 918	trombocitopenia
#16	AnnotatorNotes T19	C0040034; Thrombocytopenia; Disease or Syndrome
T20	PROC 1142 1161	Número de plaquetas
T21	DISO 984 997	esquistocitos
T22	PROC 1028 1045	tratamiento de IP
#17	AnnotatorNotes T22	C0032113; Plasma Exchange; Therapeutic or Preventive Procedure
T23	PROC 1067 1084	tratamiento de IP
#18	AnnotatorNotes T23	C0032113; Plasma Exchange; Therapeutic or Preventive Procedure
T24	PROC 1097 1111	aleatorización
#19	AnnotatorNotes T24	C0034656; Randomization; Research Activity
T25	ANAT 1152 1161	plaquetas
#20	AnnotatorNotes T25	C0005821; Blood Platelets; Cell
T26	CHEM 1191 1201	creatinina
#21	AnnotatorNotes T26	C0010294; creatinine; Biologically Active Substance · Organic Chemical
T27	ANAT 1202 1208	sérica
#22	AnnotatorNotes T27	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T28	ANAT 1249 1258	plaquetas
#23	AnnotatorNotes T28	C0005821; Blood Platelets; Cell
T29	DISO 1303 1318	trombocitopenia
#24	AnnotatorNotes T29	C0040034; Thrombocytopenia; Disease or Syndrome
T30	DISO 1323 1336	PTT congénita
#25	AnnotatorNotes T30	C1268935; Congenital Thrombotic Thrombocytopenic Purpura; Disease or Syndrome
T31	PROC 1456 1470	ensayo clínico
#26	AnnotatorNotes T31	C0008976; Clinical Trials; Research Activity
T32	CHEM 1475 1487	caplacizumab
#27	AnnotatorNotes T32	C3713057; caplacizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T33	CHEM 1503 1515	caplacizumab
#28	AnnotatorNotes T33	C3713057; caplacizumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T34	PROC 1554 1565	tratamiento
#29	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	DISO 488 520	viscosidad excesiva de la sangre
#30	AnnotatorNotes T35	C0948013; Increased blood viscosity (finding); Finding
T36	ANAT 961 974	eritrocitaria
#31	AnnotatorNotes T36	C0014792; Erythrocytes; Cell
T37	PROC 1182 1208	Nivel de creatinina sérica
T38	Date 13 17	2015
T39	LIVB 93 102	pacientes
#32	AnnotatorNotes T39	C0030705; Patients; Patient or Disabled Group
T40	LIVB 349 358	pacientes
#33	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	LIVB 709 729	Adulto varón o mujer
#34	AnnotatorNotes T41	C0001675; Adult; Age Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T43	Age 730 743	> ó = 18 años
T44	Frequency 1046 1052	diario
T45	PHYS 1393 1401	Embarazo
#35	AnnotatorNotes T45	C0032961; Pregnancy; Organism Function
T46	PHYS 1404 1413	lactancia
#36	AnnotatorNotes T46	C0006147; Breast Feeding; Organism Function | C0022925; Lactation; Organ or Tissue Function
T47	LIVB 1418 1427	Pacientes
#37	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T42	Observation 921 974	evidencia microscópica de fragmentación eritrocitaria
A1	Population_data T41 Age
A2	Status T33 History_of
A3	Status T32 History_of
A4	Status T31 History_of
A5	Status T34 History_of
A6	Status T30 History_of
#38	AnnotatorNotes T4	C0282461; Phase 3 Clinical Trials; Research Activity + C0013072; Double-Blind Method; Research Activity  +C2826345; Parallel Study; Research Activity + C0599724; placebo controlled study; Research Activity · Intellectual Product + C0034656; Randomization; Research Activity
#39	AnnotatorNotes T5	C0511730; Identify product efficacy and safety issues; Health Care Activity
#40	AnnotatorNotes T20	C0032181; Platelet Count measurement; Laboratory Procedure
#41	AnnotatorNotes T18	C0032181; Platelet Count measurement; Laboratory Procedure
#42	AnnotatorNotes T37	C0201976; Creatinine measurement, serum (procedure); Laboratory Procedure
R1	Experiences Arg1:T39 Arg2:T2	
R2	Experiences Arg1:T39 Arg2:T3	
R3	Experiences Arg1:T40 Arg2:T6	
R4	Experiences Arg1:T40 Arg2:T7	
R5	Location_of Arg1:T10 Arg2:T35	
R6	Causes Arg1:T8 Arg2:T35	
R7	Causes Arg1:T8 Arg2:T11	
R8	Location_of Arg1:T12 Arg2:T11	
R9	Location_of Arg1:T13 Arg2:T11	
R10	Has_Age Arg1:T41 Arg2:T43	
R11	Overlap Arg1:T15 Arg2:T43	
T48	Quantifier_or_Qualifier 868 875	inicial
R12	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T48	
T49	Quantifier_or_Qualifier 878 888	recurrente
R13	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T49	
R14	Location_of Arg1:T36 Arg2:T42	
R15	Causes Arg1:T17 Arg2:T19	
R16	Causes Arg1:T17 Arg2:T42	
R17	Causes Arg1:T17 Arg2:T21	
R18	Has_Frequency Arg1:T22 Arg2:T44	
R19	Before Arg1:T23 Arg2:T24	
R20	Before Arg1:T22 Arg2:T24	
T50	Result_or_Value 1162 1178	> ó = 100×10E9/l
R21	Has_Result_or_Value Arg1:T20 Arg2:T50	
T51	Result_or_Value 1209 1220	>200 µmol/l
R22	Location_of Arg1:T27 Arg2:T37	
R23	Has_Result_or_Value Arg1:T37 Arg2:T51	
T52	Result_or_Value 1263 1273	> 30×109/l
R24	Has_Result_or_Value Arg1:T18 Arg2:T52	
T53	Observation 1367 1388	entrada en el estudio
#43	AnnotatorNotes T53	C0422726; Patient entered into trial; Finding
R25	Overlap Arg1:T30 Arg2:T53	
R27	Experiences Arg1:T47 Arg2:T32	
R28	Experiences Arg1:T47 Arg2:T33	
T54	Observation 1277 1289	Otras causas
R29	Causes Arg1:T54 Arg2:T29	
T55	Observation 1529 1565	se desconoce el brazo de tratamiento
#44	AnnotatorNotes T55	C0580964; Drug treatment unknown; Finding (?)
#45	AnnotatorNotes T21	C0855795; Red blood cell schistocytes present; Finding
R30	Has_Frequency Arg1:T23 Arg2:T44	
T56	Observation 1418 1470	Pacientes incluidos previamente en un ensayo clínico
A7	Status T56 History_of
#46	AnnotatorNotes T56	C1278516; Patient participation status; Finding
R33	Overlap Arg1:T19 Arg2:T42	
R34	Overlap Arg1:T19 Arg2:T21	
#47	AnnotatorNotes T48	C0205265; Initially; Temporal Concept
#48	AnnotatorNotes T49	C2945760; Recurrent; Temporal Concept
#49	AnnotatorNotes T54	C5555349; Other Disease Etiology; Finding
A8	Experiencer T39 Patient
A9	Experiencer T40 Patient
A10	Experiencer T41 Patient
A11	Experiencer T47 Patient
A12	Assertion T52 Hypothetical
